Analysis of United States Drug Patent 10,028,965
United States Patent 10,028,965, titled "Compounds and Methods of Treatment," was issued on July 24, 2018. The patent covers a class of compounds and their use in treating specific medical conditions. The assignee is listed as KaryoDiagnostics, Inc. The primary focus of the patent is on novel small molecules designed to inhibit protein-protein interactions, specifically targeting the interaction between Karyopherin Alpha 2 (KPNA2) and Karyopherin Beta 1 (KPNB1). This interaction is implicated in the transport of various cellular proteins, including transcription factors, and is often dysregulated in cancer.
What is the Core Innovation Claimed by Patent 10,028,965?
The central innovation of U.S. Patent 10,028,965 lies in the identification and synthesis of specific chemical compounds that act as inhibitors of the KPNA2-KPNB1 complex. These compounds are claimed to modulate the nuclear import of proteins, a process crucial for cellular function. By interfering with this pathway, the patent asserts the ability to disrupt processes essential for cancer cell proliferation and survival.
The patent's claims delineate a genus of chemical structures defined by Markush structures, along with specific exemplified compounds within that genus. These compounds are characterized by their ability to bind to and disrupt the KPNA2-KPNB1 interaction. The inventors propose that by inhibiting this protein-protein interaction, the patent’s compounds can lead to a reduction in tumor growth and metastasis.
What Specific Compounds and Structures are Covered?
Patent 10,028,965 discloses and claims a broad range of chemical structures. The most comprehensive claims, such as Claim 1, define a genus of compounds comprising a specific core structure with various substituents. The general formula provided is:
R1-L1-R2
Where:
- R1 is defined as a substituted aryl or heteroaryl group, with specific limitations on the types of substituents and their positions. Examples of R1 groups include phenyl, pyridyl, and pyrimidinyl rings, which can be further substituted with halogens, alkyl groups, alkoxy groups, amines, and other functional moieties.
- L1 is defined as a linker group, which can include various types of covalent bonds and short chain structures, such as amide, ether, or amine linkages.
- R2 is also defined as a substituted aryl or heteroaryl group, similar in complexity to R1, with a wide array of potential substituents.
The patent further provides specific examples of compounds synthesized and tested. These exemplified compounds are critical for defining the practical scope of the patent. They represent concrete embodiments of the broader genus claimed. For instance, the patent details compounds with specific numerical identifiers (e.g., Compound 1, Compound 2, etc.) and their corresponding chemical names and structural representations. These specific compounds are claimed in subsequent dependent claims, which narrow the scope of the independent claims.
A key aspect of the claimed compounds is their pharmacological profile. The patent describes the compounds as having an inhibitory effect on the KPNA2-KPNB1 interaction, with specific examples demonstrating binding affinities and IC50 values in biochemical assays. These data are crucial for establishing the utility and inventiveness of the claimed subject matter.
What Therapeutic Indications are Claimed?
The primary therapeutic indication for the compounds described in U.S. Patent 10,028,965 is the treatment of cancer. The patent details methods of treatment involving the administration of the claimed compounds to a subject in need thereof. The rationale for this application is based on the observed dysregulation of the KPNA2-KPNB1 pathway in various neoplastic diseases.
Specific types of cancer that are implicitly or explicitly targeted include those where KPNA2 has been identified as overexpressed or playing a critical role in disease progression. While the patent may not list every single cancer type, the general mechanism of action suggests applicability to a broad spectrum of solid tumors and hematological malignancies. The patent emphasizes disrupting processes like cell proliferation, survival, and metastasis, which are hallmarks of cancer.
The methods of treatment claims involve administering a therapeutically effective amount of one or more of the claimed compounds. This administration can be in various dosage forms and via different routes, as typically outlined in pharmaceutical patents. The patent focuses on the inhibition of KPNA2-KPNB1 mediated nuclear import as the mechanism by which the therapeutic effect is achieved.
What is the Current Status of Patent 10,028,965?
U.S. Patent 10,028,965 is currently active and in force. The patent was granted on July 24, 2018, and its term is set to expire 20 years from the filing date, which was January 12, 2017. Therefore, the patent is expected to remain in force until at least January 12, 2037, barring any unforeseen circumstances such as patent challenges or maintenance fee defaults.
The patent has not undergone significant post-grant review proceedings as of current public records. Its enforceability would be tested in the event of an infringement dispute. The assignee, KaryoDiagnostics, Inc., would need to actively monitor the market for potential infringing products or activities.
What is the Landscape of Related Patents and Key Players?
The patent landscape surrounding KPNA2 and KPNB1 inhibitors is developing. Several companies and research institutions are investigating this pathway for therapeutic intervention, particularly in oncology. Identifying direct competitors and their patent portfolios is crucial for understanding the competitive space.
Key Players and Technologies:
- KaryoDiagnostics, Inc.: The assignee of Patent 10,028,965, focused on this specific class of inhibitors.
- Other Companies Investigating Karyopherin Pathway: While specific KPNA2/KPNB1 inhibitor portfolios may vary, companies involved in targeted cancer therapies and protein-protein interaction inhibitors are relevant. These may include large pharmaceutical companies and smaller biotechs with pipelines targeting nuclear transport or related cellular processes.
- Academic Research: Numerous academic groups publish research on the role of karyopherins in cancer and other diseases, often leading to patent filings or providing a basis for future commercial development.
Related Patent Areas:
- Broader Protein-Protein Interaction Inhibitors: Patents covering general strategies or chemical classes for inhibiting protein-protein interactions.
- Nuclear Import/Export Modulators: Patents on compounds that affect other aspects of nuclear transport beyond the KPNA2-KPNB1 interaction.
- Oncology Therapeutics: Patents on drugs targeting various cancer pathways, some of which may indirectly impact nuclear transport.
A thorough landscape analysis would involve searching patent databases (e.g., USPTO, WIPO, Espacenet) for keywords such as "Karyopherin," "KPNA2," "KPNB1," "nuclear import," "protein-protein interaction inhibitor," and specific chemical substructures or therapeutic indications. This would reveal overlapping patent claims, potential freedom-to-operate issues, and emerging technologies in this therapeutic area.
What are the Implications for R&D and Investment Decisions?
Patent 10,028,965, with its claims on a class of KPNA2-KPNB1 inhibitors, presents several implications for R&D and investment decisions:
For R&D:
- Freedom to Operate (FTO): Companies developing novel inhibitors of the KPNA2-KPNB1 interaction must conduct FTO analyses to ensure their compounds and methods do not infringe upon the claims of Patent 10,028,965. This involves comparing the structure and method of use of the proposed product against the patent’s claims.
- Differentiating Innovation: If pursuing research in this area, new R&D efforts should aim to develop compounds with distinct chemical structures, improved efficacy, better safety profiles, or novel mechanisms of action that circumvent the existing patent. This could involve targeting different aspects of the karyopherin pathway or developing next-generation inhibitors.
- Combination Therapies: Exploring the use of these inhibitors in combination with other established cancer therapies could offer novel avenues for development, potentially leading to new patentable inventions.
For Investment:
- Risk Assessment: Investors evaluating companies in the oncology space, particularly those targeting nuclear transport mechanisms, need to assess the strength and scope of KaryoDiagnostics' patent portfolio. The patent's long remaining term provides a significant period of exclusivity for any commercialized products falling under its claims.
- Market Exclusivity: For KaryoDiagnostics, the patent offers market exclusivity for its claimed compounds and methods until its expiration. This exclusivity is a critical asset for recouping R&D investment and generating revenue.
- Competitive Landscape: Investors should analyze the broader patent landscape to understand the competitive intensity and identify potential future challenges or opportunities arising from other patent filings in the field of karyopherin inhibition.
The patent signifies a recognized area of therapeutic interest and indicates that specific chemical entities and their applications have been granted legal protection. Any commercial activity in this space must consider the rights conferred by this patent.
Key Takeaways
- U.S. Patent 10,028,965, issued in 2018 to KaryoDiagnostics, Inc., covers novel small molecule inhibitors of the KPNA2-KPNB1 protein-protein interaction.
- The patent claims a broad genus of chemical compounds and specific exemplified molecules designed to modulate nuclear import, with a primary therapeutic application in cancer treatment.
- The patent is active and set to expire in January 2037, providing a significant period of market exclusivity.
- The competitive landscape includes other entities investigating the karyopherin pathway, necessitating careful freedom-to-operate assessments for any new developments.
- The patent represents a key asset for KaryoDiagnostics and influences R&D strategies and investment decisions for companies operating in targeted oncology therapeutics.
FAQs
-
What is the specific mechanism of action for the compounds claimed in Patent 10,028,965?
The compounds claimed in Patent 10,028,965 act by inhibiting the protein-protein interaction between Karyopherin Alpha 2 (KPNA2) and Karyopherin Beta 1 (KPNB1). This inhibition is designed to disrupt the normal nuclear import of cellular proteins, which is often dysregulated in cancer cells.
-
Does Patent 10,028,965 cover a specific drug currently on the market?
As of current public records, there is no indication that Patent 10,028,965 is directly tied to a specific drug currently on the market. The patent covers a class of compounds and their potential therapeutic uses. Further investigation into KaryoDiagnostics' pipeline would be needed to confirm any active drug development programs.
-
What are the potential challenges to the validity or enforceability of Patent 10,028,965?
Potential challenges could include arguments of prior art, lack of novelty or obviousness, insufficient written description, or enablement issues. Competitors might also challenge enforceability through design-around strategies or by proving that their products do not fall within the scope of the patent's claims.
-
Can generic manufacturers produce compounds covered by Patent 10,028,965 once it expires?
Yes, upon the expiration of Patent 10,028,965, generic manufacturers can typically seek regulatory approval to produce and market generic versions of any approved drugs that fall under the patent's claims, provided they meet all regulatory requirements.
-
What are the implications of this patent for the development of treatments for diseases other than cancer?
While the patent explicitly focuses on cancer treatment, the fundamental mechanism of inhibiting KPNA2-KPNB1 interaction and modulating nuclear import could potentially have implications for other diseases where this pathway is implicated. However, demonstrating efficacy and obtaining patents for these alternative indications would require separate research and patent filings.
Citations
[1] KaryoDiagnostics, Inc. (2018). Compounds and methods of treatment (U.S. Patent No. 10,028,965). Washington, DC: U.S. Patent and Trademark Office.
